Mathew Garnett

Mathew Garnett, PhD is a Senior Faculty member and leads the Translational Cancer Genomics laboratory at the Wellcome Sanger Institute, Cambridge UK. His research aims to understand how genetic changes contribute to cancer and to identify molecular biomarkers that will improve the development of new cancer therapies using high-throughput chemical and genetic screens in cancer cell lines and organoids. His research team have contributed to the generation of widely used reference datasets and tools including resources such as the Genomics of Drug Sensitivity in Cancer project, the Cancer Dependency Map at Sanger, and the Human Cancer Model Initiative. Mathew is also a founder and advisor for Mosaic Therapeutics (https://mosaic-tx.com/) which is developing molecular-guided cancer drug combinations. After obtaining a BSc in Biochemistry (Hons.) at the University of British Columbia, Canada, Mathew completed his PhD with Prof. Richard Marais at the Institute of Cancer Research (London, UK) on the characterisation of BRAF as a cancer gene. In 2005 Mathew moved to the laboratory of Prof. Ashok Venkitaraman (Cambridge, UK) for his post-doctoral research, where he discovered a new regulator of cell division. Mathew joined the Sanger Institute in 2009 as a Senior Staff Scientist and established his own laboratory in 2014.

Relevant Publications

• Gonçalves E, Poulos RC, Cai Z, Barthorpe S, Manda SS, Lucas N, Beck A, Bucio-Noble D, Dausmann M, Hall C, Hecker M, Koh J, Lightfoot H, Mahboob S, Mali I, Morris J, Richardson L, Seneviratne AJ, Shepherd R, Sykes E, Thomas F, Valentini S, Williams SG, Wu Y, Xavier D, MacKenzie KL, Hains PG, Tully B, Robinson PJ, Zhong Q, Garnett MJ, Reddel RR. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell. 2022 Aug 8;40(8):835-849.e8. doi: 10.1016/j.ccell.2022.06.010. PMID: 35839778; PMCID: PMC9387775.
• Jaaks, P., Coker, E. A., Vis, D. J., Edwards, O., Carpenter, E. F., Leto, S. M., Dwane, L., Sassi, F., Lightfoot, H., Barthorpe, S., van der Meer, D., Yang, W., Beck, A., Mironenko, T., Hall, C., Hall, J., Mali, I., Richardson, L., Tolley, C., Morris, J., Thomas F, Lleshi E, Aben N, Benes CH, Bertotti A, Trusolino L, Wessels L, Garnett MJ. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature. 2022 Mar;603(7899):166-173. doi: 10.1038/s41586-022-04437-2. PMID: 35197630; PMCID: PMC8891012.
• Picco G, Cattaneo CM, van Vliet EJ, Crisafulli G, Rospo G, Consonni S, Vieira SF, Sanchez Rodriguez I, Cancelliere C, Banerjee R, Schipper LJ, Oddo D, Dijkstra KK, Cinatl J, Michaelis M, Yang F, Uk Group CMN, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Arena S, Voest EE, Bardelli A, Garnett MJ. Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy. Cancer Discov. 2021 Apr 9:candisc.1508.2020. doi: 10.1158/2159-8290.CD-20-1508. PMID: 33837064.
• Gonçalves E, Segura-Cabrera A, Pacini C, Picco G, Behan FM, Jaaks P, Coker EA, van der Meer D, Barthorpe A, Lightfoot H, Mironenko T, Beck A, Richardson L, Yang W, Lleshi E, Hall J, Tolley C, Hall C, Mali I, Thomas F, Morris J, Leach AR, Lynch JT, Sidders B, Crafter C, Iorio F, Fawell S, Garnett MJ. Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens. Mol Syst Biol. 2020 Jul;16(7):e9405. doi: 10.15252/msb.20199405. PMID: 32627965; PMCID: PMC7336273.
• Behan FM*, Iorio F*, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K^, Garnett MJ. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019 Apr; 568(7753): 511-516. PMID: 30971826.
• van der Meer D*, Barthorpe S*, Yang W, Lightfoot H, Hall C, Gilbert J, Francies HE, Garnett MJ^. Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models. Nucleic Acids Res. 2018 Sep 27. PMID: 30260411.
• Li X, Francies HE, Secrier M, Perner J, Miremadi A, Galeano-Dalmau N, Barendt WJ, Letchford L, Leyden GM, Goffin EK, Barthorpe A, Lightfoot H, Chen E, Gilbert J, Noorani A, Devonshire G, Bower L, Grantham A, MacRae S, Grehan N, Wedge DC, Fitzgerald RC, Garnett MJ. Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. Nat Commun. 2018 Jul 30;9(1):2983. PMID: 30061675; PMCID:PMC6065407.
• Iorio F*, Knijnenburg TA*, Vis DJ*, Bignell GR*, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, Heyn H, Deng X, Egan RK, Liu Q, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber DA, Stratton MR, Benes CH, Wessels LF, Saez-Rodriguez J, McDermott U^, Garnett MJ^. A Landscape of Pharmacogenomic Interactions in Cancer. Cell. 2016 Jul 28;166(3):740-54. PMID: 27397505. PMCID: 4967469